AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug
AstraZeneca and Amgen rolled out Phase IIb data on their late-stage drug tezepelumab late on Wednesday, spotlighting some dramatic results for a therapy they believe could have megablockbuster potential for the broad-based treatment of uncontrolled asthma.
Bottom line: Treatment-resistant patients in the drug arm taking a medley of doses saw their annual exacerbation rate slashed anywhere from 61% to 71%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.